“极光加速器
“极光加速器
Luis
Supply Chain at Apellis
“极光加速器
Learn More
“极光加速器
“极光加速器
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
“极光加速器
Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)
w加速器官网
Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
@ApellisPharma
“极光加速器
FOR PATIENTS
“极光加速器
for paroxysmal nocturnal hemoglobinuria, geographic atrophy,
C3 glomerulopathy, and cold agglutinin disease.
“极光加速器
are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.
CLINICAL TRIALS“极光加速器
so that Alexander, who is living with C3 glomerulopathy, can take his pug for a hike
We challenge conventional thinking and always question if there's a better way.
Join Us
Patricia
Quality Assurance at Apellis
This website is intended for residents of the U.S.